Considering that TM-V exhibits only moderate DPAGT1 inhibitory activity, the tumor regressions reported in TM-V–treated models are unlikely to be explained solely by DPAGT1 inhibition but may instead reflect a combination of partial target engagement and off-target cytotoxic mechanisms. The gene discussed is DPAGT1; the disease is neoplasm.